FC070: Lumasiran for Patients with Primary Hyperoxaluria Type 1 with Impaired Kidney Function: Data from the 6-Month Analysis of the Phase 3 Illuminate-C Trial
Year: 2022
Type: conference-abstract
Authors: Jaap Groothoff, Mini Michael, Hadas Shasha-Lavsky, John Lieske, Yaacov Frishberg, Eva Simkova, Anne-Laure Sellier-Leclerc, Devresse Arnaud, Fitsum Guebre-Egziabher, Sevcan Azime Bakkaloglu, Chebl Mourani, Rola Saqan, Richard Singer, Richard Willey, Bahru Habtemariam, Ishir Bhan, John Gansner, Daniella Magen
Institutions: Emma Kinderziekenhuis, University of Amsterdam, Baylor College of Medicine, Texas Children's Hospital, Bar-Ilan University, Mayo Clinic, Hebrew University of Jerusalem, Shaare Zedek Medical Center, Bikur Cholim Hospital, Al Jalila Foundation, Inserm, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Cliniques Universitaires Saint-Luc, Hôpital Edouard Herriot, Gazi University, Hôtel-Dieu de France, Jordan University of Science and Technology, Alnylam Pharmaceuticals (United States), Rambam Health Care Campus
Language: English
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4229010393